News

Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.

A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.

New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.

Sellas estimated cash and cash equivalents of $138.3 million as of June 30.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.

During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.

A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.

The company entered a quiet period for trial-specific updates ahead of topline data.

Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]

CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.

CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.

Gamma Investing cut its SLS stake by 259 shares, or 32%, holding 556 shares worth about $8,210 as of June 30.

First Financial Bank also held 10,000 SLS shares, valued at $147,600.

Endpoint Area listed Nov. 30 as the expected catalyst timing for Sellas’ Phase 3 GPS trial.

Buyout chatter is building after change-of-control updates and a market-cap surge to over $1.5 billion.

SELLAS Life Sciences Group (NasdaqCM:SLS) has amended executive employment and severance agreements tied to a potential change in control. The move comes as the company approaches final analysis of its pivotal Phase 3 acute myeloid leukemia (AML) immunotherapy trial. These contract changes are increasing speculation around potential merger or acquisition activity involving SELLAS Life Sciences. SELLAS Life Sciences Group is drawing renewed investor attention as its updated change in control...

Recently updated change-of-control terms also fueled buyout chatter by outlining executive payouts and full equity acceleration related to a change in control.

Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS. SELLAS Life Sciences Group, Inc.’s share was trading at $9.07 as of June 23rd. SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical […]

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits. Sellas Life Sciences extended its winning streak to a 6th straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition. In a disclosure, Sellas Life Sciences Group […]

CEO Angelos Stergiou's equity award will vest over four years, increasing his ownership stake to 1.76 million shares.

Shareholders are set to vote on five proposals, including one to increase the number of shares available under the 2023 Equity Incentive Plan.

The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.

Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.

Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.

The company plans to move quickly toward a pre-BLA meeting with the FDA and a potential filing if the REGAL trial reports positive results.

Retail speculation intensified as short interest in SLS climbed to a record high of 30.7% ahead of the final Regal catalyst.

Beyond leukemia, Sellas said GPS could potentially expand into up to 20 different tumor types.